Company Profile

Dr. Andrew Alt, Director of Center for Chemical Genomics at the Life Sciences Institute (University of Michigan) is the partial owner of a for-profit company called Eleven Therapeutics Corporation a company formed 2018 to commercialize allosteric modulators for the opioid receptors to treat pain. Principals of the firm requested an option from the University of Michigan to the University’s rights associated with the following technology: UM OTT File No. 2019-039, entitled: “Allosteric Modulators of Opioid Receptors” (Inventors: John Traynor, Andrew White) The Office of Technology Transfer selected the Company as a University partner and negotiated the terms of the proposed Agreement in accordance with University policy and its accepted licensing principles.